Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
Vanda Pharmaceuticals (NASDAQ: VNDA) has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025, after market close. The company will host a conference call at 4:30 PM ET the same day to discuss quarterly results and corporate activities. Investors can join via phone using the numbers 1-800-715-9871 (domestic) or 1-646-307-1963 (international) with passcode 9941754.
The call will be simultaneously broadcast and archived on www.vandapharma.com. A replay will be available from 8:30 PM ET on May 7 until 11:59 PM ET on May 14, 2025, accessible at 1-800-770-2030 (domestic) or 1-609-800-9909 (international) using the same passcode.
Vanda Pharmaceuticals (NASDAQ: VNDA) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per mercoledì 7 maggio 2025, dopo la chiusura del mercato. La società terrà una conference call alle 16:30 ET dello stesso giorno per discutere i risultati trimestrali e le attività aziendali. Gli investitori potranno partecipare telefonicamente utilizzando i numeri 1-800-715-9871 (nazionale) o 1-646-307-1963 (internazionale) con il codice di accesso 9941754.
La chiamata sarà trasmessa in diretta e archiviata su www.vandapharma.com. Una registrazione sarà disponibile dalle 20:30 ET del 7 maggio fino alle 23:59 ET del 14 maggio 2025, accessibile al numero 1-800-770-2030 (nazionale) o 1-609-800-9909 (internazionale) utilizzando lo stesso codice di accesso.
Vanda Pharmaceuticals (NASDAQ: VNDA) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el miércoles 7 de mayo de 2025, después del cierre del mercado. La compañía realizará una conferencia telefónica a las 4:30 PM ET el mismo día para discutir los resultados trimestrales y las actividades corporativas. Los inversores pueden unirse por teléfono usando los números 1-800-715-9871 (nacional) o 1-646-307-1963 (internacional) con el código de acceso 9941754.
La llamada será transmitida simultáneamente y archivada en www.vandapharma.com. Una repetición estará disponible desde las 8:30 PM ET del 7 de mayo hasta las 11:59 PM ET del 14 de mayo de 2025, accesible en 1-800-770-2030 (nacional) o 1-609-800-9909 (internacional) usando el mismo código de acceso.
Vanda Pharmaceuticals (NASDAQ: VNDA)는 2025년 1분기 재무 실적 발표를 2025년 5월 7일 수요일 장 마감 후로 예정했습니다. 회사는 같은 날 오후 4:30 ET에 분기 실적 및 기업 활동에 대해 논의하는 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 국내 전화번호 1-800-715-9871 또는 국제 전화번호 1-646-307-1963을 통해 접속 코드 9941754를 사용하여 참여할 수 있습니다.
콜은 www.vandapharma.com에서 동시에 생중계 및 아카이브됩니다. 재청취는 2025년 5월 7일 오후 8:30 ET부터 5월 14일 오후 11:59 ET까지 가능하며, 국내는 1-800-770-2030, 국제는 1-609-800-9909 번호와 동일한 접속 코드를 사용하여 이용할 수 있습니다.
Vanda Pharmaceuticals (NASDAQ: VNDA) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mercredi 7 mai 2025, après la clôture du marché. La société tiendra une conférence téléphonique à 16h30 ET le même jour pour discuter des résultats trimestriels et des activités de l'entreprise. Les investisseurs peuvent participer par téléphone en composant les numéros 1-800-715-9871 (domestique) ou 1-646-307-1963 (international) avec le code d'accès 9941754.
L'appel sera diffusé simultanément et archivé sur www.vandapharma.com. Une rediffusion sera disponible à partir de 20h30 ET le 7 mai jusqu'à 23h59 ET le 14 mai 2025, accessible au 1-800-770-2030 (domestique) ou 1-609-800-9909 (international) en utilisant le même code d'accès.
Vanda Pharmaceuticals (NASDAQ: VNDA) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Mittwoch, den 7. Mai 2025, nach Börsenschluss, geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Quartalsergebnisse und Unternehmensaktivitäten zu besprechen. Investoren können über die Telefonnummern 1-800-715-9871 (national) oder 1-646-307-1963 (international) mit dem Zugangscode 9941754 teilnehmen.
Der Anruf wird gleichzeitig auf www.vandapharma.com übertragen und archiviert. Eine Wiedergabe ist vom 7. Mai, 20:30 Uhr ET, bis zum 14. Mai 2025, 23:59 Uhr ET, unter den Nummern 1-800-770-2030 (national) oder 1-609-800-9909 (international) mit demselben Zugangscode verfügbar.
- None.
- None.
Conference Call and Webcast to Follow
Vanda will host a conference call at 4:30 PM ET on Wednesday, May 7, 2025, during which management will discuss the first quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9941754.
The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Wednesday, May 7, 2025, beginning at 8:30 PM ET and will be accessible until Wednesday, May 14, 2025, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 9941754.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-first-quarter-2025-financial-results-on-may-7-2025-302445033.html
SOURCE Vanda Pharmaceuticals Inc.
FAQ
When will Vanda Pharmaceuticals (VNDA) report Q1 2025 earnings?
What time is Vanda Pharmaceuticals' (VNDA) Q1 2025 earnings call?
How can I access Vanda Pharmaceuticals' Q1 2025 earnings call?
How long will Vanda Pharmaceuticals' Q1 2025 earnings call replay be available?
